Background FK506 is widely used in organ transplantation and causes hyperte
nsion. However. little is known about the impact of the drug on the cardiov
ascular system.
Methods. We therefore investigated the effect of FK506 on resistance artery
and blood pressure responsiveness to vasoconstrictors and vasodilators. St
udies were conducted in vitro using human and murine resistance artery, ex
vivo in resistance artery isolated from rats treated with FK506 (6 mg/kg/da
y), and in vivo in conscious. treated animals.
Results. In vitro exposure (24 hr) of human and rat resistance artery to FK
506 (1000 ng/ml) increased the sensitivity to norepinephrine (NE) and impai
red the response to acetylcholine (Ach) and sodium nitroprusside (SNp). In
contrast, arteries isolated from rats given FK506 for eight days showed a r
educed sensitivity to NE (P < 0.05) and a normal endothelium-dependent rela
xation. Their incubation with L-arginine caused a significant reduction in
Ach sensitivity in the FK506 group (P < 0.05) but not in controls, suggesti
ng enhancement of nitric oxide production by the drug. The sensitivity to S
Np was reduced, as in the in vitro experiments (P < 0.05). Rats given FK506
for eight days presented blood pressure similar to that in controls but al
so presented signs of a compensatory response to excess vasodilation: tachy
cardia (P < 0.01). reduced blood pressure sensitivity to NE and Ach. blunte
d heart rate response to both agonists, and exaggerated hypotension at high
doses of Ach. After 21 days of treatment, blood pressure remained similar
to that in controls, but resistance artery showed further functional deteri
oration, with significant impairment of the maximum responses to Ach and to
SNp.
Conclusion. FK506 presents significant vascular toxicity affecting mainly s
mooth muscle relaxation and alters vascular hemodynamics. The data suggest
that similar cardiovascular changes may occur in transplant patients and re
present the forerunner of hypertension often seen with more prolonged use o
f the drug.